Metastatic melanoma: can FDG-PET predict success of anti-PD-1 therapy and help determine when it can be discontinued?

Saved in:
Bibliographic Details
Published in:European journal of nuclear medicine and molecular imaging Vol. 47; no. 10; pp. 2227 - 2232
Main Author: Hindié, Elif
Format: Journal Article
Language:English
Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.09.2020
Springer Nature B.V
Subjects:
Cardiology
CTLA-4 Antigen - therapeutic use
Editorial
Fluorodeoxyglucose F18
Humans
Imaging
Immune Checkpoint Inhibitors
Immunotherapy
Medicine
Medicine & Public Health
Melanoma
Melanoma - diagnostic imaging
Melanoma - drug therapy
Metastases
Nuclear Medicine
Oncology
Oncology – Chest
Orthopedics
PD-1 protein
Positron-Emission Tomography
Prognosis
Programmed Cell Death 1 Receptor
Radiology
Skin Neoplasms - diagnostic imaging
Skin Neoplasms - drug therapy
ISSN:1619-7070, 1619-7089, 1619-7089
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Bibliography:SourceType-Scholarly Journals-1
content type line 14
ObjectType-Editorial-2
ObjectType-Commentary-1
content type line 23
ISSN:1619-7070
1619-7089
1619-7089
DOI:10.1007/s00259-020-04826-7